文献速递胃肠动力与功能性疾病消化内镜

双倍剂量PPI治疗期间pH阻抗监测对反流管理升级需求的预测价值

Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management.
PubMed 文献 · Gastroenterology · 2021-07-14

研究分析双倍剂量PPI治疗期间pH阻抗监测数据,比较健康志愿者与确诊GERD患者(欧洲烧心为主队列和北美反流为主队列),发现传统及新反流指标在PPI应答者与非应答者间无差异,但AET>4%且反流>80次的组合与治疗非应答相关,其中反流为主患者更显著,此类患者接受侵入性管理后多改善。

要点

  • 双倍PPI期间pH阻抗指标在应答者与非应答者间无显著差异。
  • AET>4%且反流>80次组合在反流为主GERD中占40.5%,其中82.4%非应答。

核心结论

  • 双倍PPI期间异常pH阻抗指标组合与确诊GERD患者PPI非应答相关,可指导治疗升级包括手术,尤其反流为主GERD。

研究设计与样本

  • 分析双倍PPI期间pH阻抗研究:健康志愿者66例(中位年龄37.5岁,43.9%女性),欧洲烧心为主GERD 43例(中位年龄57.0岁,55.8%女性),北美反流为主GERD 42例(中位年龄41.6岁,42.9%女性)。

主要发现

  • AET>4%且反流>80次的组合在烧心为主和反流为主患者中分别占32.6%和40.5%,其中57.1%和82.4%报告非应答;85%具此指标者经侵入性GERD管理改善。

关键数值与推荐

  • AET>4%且反流>80次组合与PPI非应答相关,85%经侵入性管理改善。

临床怎么用

  • 双倍PPI期间pH阻抗显示AET>4%且反流>80次或反流≥40次时,提示PPI非应答,可考虑升级治疗包括手术,尤其反流为主GERD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Acid exposure time (AET) and reflux episode thresholds from the Lyon Consensus may not apply for pH impedance studies performed while on proton pump inhibitor (PPI) therapy. We aimed to determine metrics from "on PPI" pH impedance studies predicting need for escalation of therapy. METHODS: De-identified pH impedance studies performed while on twice-daily PPI (Diversatek, Boulder, CO) in healthy volunteers (n = 66, median age 37.5 years, 43.9% female), and patients with proven gastroesophageal reflux disease (GERD) (European heartburn-predominant cohort: n = 43, median age 57.0 years, 55.8% female; North American regurgitation-predominant cohort: n = 42, median age 41.6 years, 42.9% female) were analyzed. Median values and interquartile ranges for pH impedance metrics in healthy volunteers were compared with proven GERD patients with and without 50% symptom improvement on validated measures. Receiver operating characteristic (ROC) analyses identified optimal thresholds predicting symptom response. RESULTS: Both conventional and novel reflux metrics were similar between PPI responders and nonresponders (P ≥ .1 for each) despite differences from healthy volunteers. Combinations of metrics associated with conclusively abnormal reflux burden (AET >4%, >80 reflux episodes) were seen in 32.6% and 40.5% of heartburn and regurgitation-predominant patients, respectively, 57.1% and 82.4% of whom reported nonresponse; and 85% with these metrics improved with invasive GERD management. On ROC analysis, AET threshold of 0.5% modestly predicted nonresponse (sensitivity, 0.62; specificity, 0.51; P = .22), and 40 reflux episodes had better performance characteristics (sensitivity, 0.80; specificity, 0.51; P = .002); 79% with these metrics improved with invasive GERD management. CONCLUSION: Combinations of abnormal "on PPI" pH impedance metrics are associated with PPI nonresponse in proven GERD patients, and can be targeted for treatment escalation, including surgery, particularly in regurgitation-predominant GERD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gyawali CP, Tutuian R, Zerbib F, et al. Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management. Gastroenterology. 2021. PMID: 34270955. doi:10.1053/j.gastro.2021.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。